Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01302964 · ClinicalTrials.gov registry record · Phase 3
Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders
A Phase 3 study, sponsored by Massachusetts General Hospital.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT01302964: Completed Phase 3 study, sponsored by Massachusetts General Hospital.
NCT01302964 is a Phase 3 study that has completed, run by Massachusetts General Hospital. The registered enrollment target is 30 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01302964, a Phase 3 study, has completed, sponsored by Massachusetts General Hospital.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of mirtazapine in reducing anxiety in children with autistic disorder, Asperger's disorder and Pervasive Developmental Disorder.
Interventions
- DRUG Placebo
- DRUG Mirtazapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2010-08 |
| Est. Completion | 2017-10-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01302964
The ClinicalTrials.gov registry entry for NCT01302964 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01302964 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01302964 about?
NCT01302964 is a clinical study titled "Mirtazapine Treatment of Anxiety in Children and Adolescents With Pervasive Developmental Disorders". This study will determine the effectiveness of mirtazapine in reducing anxiety in children with autistic disorder, Asperger's disorder and Pervasive Developmental Disorder.
What is the current status of trial NCT01302964?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2010-08. Estimated completion is 2017-10-10.
What interventions are being tested in trial NCT01302964?
The interventions under investigation include: Placebo (DRUG), Mirtazapine (DRUG).
Who is sponsoring clinical trial NCT01302964?
This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.